Press Releases Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:28:33 06/03/2026 GMT			5-day change	1st Jan Change
102.71 ^CAD	-3.85%		-7.49%	-6.99%

02-13	Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT

Press Releases

02-25	Bright Minds Biosciences to Present at Upcoming Conferences	AQ
01-09	Bright Minds Biosciences Announces Closing of US$175 Million Public Offering	GL
01-08	Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock	AQ
01-06	Bright Minds Biosciences Announces Launch of US$100 Million Public Offering	AQ
01-06	Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)	AQ
01-05	Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026	AQ
11-25	Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting	AQ
11-17	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)	AQ
11-06	Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH	AQ
30/10/25	Bright Minds Biosciences to Present at Upcoming Conferences	AQ
05/09/25	BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING	AQ
04/09/25	Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model	AQ
25/08/25	Bright Minds Biosciences to Present at Upcoming Conferences	AQ
28/05/25	Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference	AQ
20/05/25	Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025	AQ
13/05/25	Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101	AQ
28/04/25	Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study	AQ
04/03/25	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research	GL
24/02/25	Bright Minds Biosciences to Participate at Three Healthcare Conferences in March	GL
24/02/25	Bright Minds Biosciences to Participate at Three Healthcare Conferences in March	AQ
07/01/25	Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer	GL
07/01/25	Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer	AQ
31/12/24	Bright Minds Biosciences : Annual Report for Fiscal Year Ending September 30, 2024 (Form 20-F)	PU
21/11/24	Bright Minds Biosciences : to Present Data at the American Epilepsy Society 2024 Annual Meeting Form 6 K	PU
21/11/24	Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting	GL